Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus rituximab in indolent mantle cell lymphoma
2024-512370-94-00Phase 2Authorised
- Sponsor
- GELTAMO
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and rituximab in mantle cell lymphoma (MCL), sponsored by GELTAMO. Primary endpoint: Complete remission rate at 12 months. Planned start Jun 2024; status: authorised.
02
Drugs
ibrutinibrituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-512370-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512370-94-00.